This page was added on 04 June 2018.
This page was updated on [date-counter-updated-date]. View history of updates
Registered for use in people aged ≥12 months.
MMR — measles-mumps-rubella combination vaccine
Lyophilised pellet in a monodose vial with a pre-filled diluent syringe.
Each 0.5 mL reconstituted dose contains:
- ≥103.0 cell culture infectious dose 50% (CCID50) of live attenuated measles virus (Schwarz strain)
- ≥103.7 CCID50 of live attenuated mumps virus (RIT 4385 strain, derived from the Jeryl Lynn strain)
- ≥103.0 CCID50 of live attenuated rubella virus (Wistar RA 27/3 strain)
- neomycin sulphate
For Product Information and Consumer Medicine Information about Priorix visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.